[Endothelin-1-induced contraction of pregnant rat myometrium: role of platelet-activating factor]. 1994

T Okawa, and H Suzuki, and C Endo, and Y Suzuki, and K Hoshi, and A Sato, and H Nakanishi
Department of Obstetrics and Gynecology, Fukushima Medical College.

UI MeSH Term Description Entries
D007213 Indomethacin A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES. Amuno,Indocid,Indocin,Indomet 140,Indometacin,Indomethacin Hydrochloride,Metindol,Osmosin
D007546 Isoquinolines A group of compounds with the heterocyclic ring structure of benzo(c)pyridine. The ring structure is characteristic of the group of opium alkaloids such as papaverine. (From Stedman, 25th ed)
D009543 Nifedipine A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure. Adalat,BAY-a-1040,Bay-1040,Cordipin,Cordipine,Corinfar,Fenigidin,Korinfar,Nifangin,Nifedipine Monohydrochloride,Nifedipine-GTIS,Procardia,Procardia XL,Vascard,BAY a 1040,BAYa1040,Bay 1040,Bay1040,Monohydrochloride, Nifedipine,Nifedipine GTIS
D010972 Platelet Activating Factor A phospholipid derivative formed by PLATELETS; BASOPHILS; NEUTROPHILS; MONOCYTES; and MACROPHAGES. It is a potent platelet aggregating agent and inducer of systemic anaphylactic symptoms, including HYPOTENSION; THROMBOCYTOPENIA; NEUTROPENIA; and BRONCHOCONSTRICTION. AGEPC,Acetyl Glyceryl Ether Phosphorylcholine,PAF-Acether,Phosphorylcholine, Acetyl Glyceryl Ether,1-Alkyl-2-acetyl-sn-glycerophosphocholine,Platelet Aggregating Factor,Platelet Aggregation Enhancing Factor,Platelet-Activating Substance,Thrombocyte Aggregating Activity,1 Alkyl 2 acetyl sn glycerophosphocholine,Aggregating Factor, Platelet,Factor, Platelet Activating,PAF Acether,Platelet Activating Substance
D010975 Platelet Aggregation Inhibitors Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. Antiaggregants, Platelet,Antiplatelet Agent,Antiplatelet Agents,Antiplatelet Drug,Blood Platelet Aggregation Inhibitor,Blood Platelet Antagonist,Blood Platelet Antiaggregant,PAR-1 Antagonists,Platelet Aggregation Inhibitor,Platelet Antagonist,Platelet Antagonists,Platelet Antiaggregant,Platelet Antiaggregants,Platelet Inhibitor,Protease-Activated Receptor-1 Antagonists,Antiplatelet Drugs,Blood Platelet Aggregation Inhibitors,Blood Platelet Antagonists,Blood Platelet Antiaggregants,Platelet Inhibitors,Agent, Antiplatelet,Aggregation Inhibitor, Platelet,Antagonist, Blood Platelet,Antagonist, Platelet,Antiaggregant, Blood Platelet,Antiaggregant, Platelet,Drug, Antiplatelet,Inhibitor, Platelet,Inhibitor, Platelet Aggregation,PAR 1 Antagonists,Platelet Antagonist, Blood,Platelet Antiaggregant, Blood,Protease Activated Receptor 1 Antagonists
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011726 Pyridinium Compounds Derivatives of PYRIDINE containing a cation C5H5NH or radical C5H6N. Compounds, Pyridinium
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

T Okawa, and H Suzuki, and C Endo, and Y Suzuki, and K Hoshi, and A Sato, and H Nakanishi
April 1998, European journal of pharmacology,
T Okawa, and H Suzuki, and C Endo, and Y Suzuki, and K Hoshi, and A Sato, and H Nakanishi
October 1993, European journal of pharmacology,
T Okawa, and H Suzuki, and C Endo, and Y Suzuki, and K Hoshi, and A Sato, and H Nakanishi
July 1998, Biology of reproduction,
T Okawa, and H Suzuki, and C Endo, and Y Suzuki, and K Hoshi, and A Sato, and H Nakanishi
January 1991, Journal of cardiovascular pharmacology,
T Okawa, and H Suzuki, and C Endo, and Y Suzuki, and K Hoshi, and A Sato, and H Nakanishi
May 1995, European journal of pharmacology,
T Okawa, and H Suzuki, and C Endo, and Y Suzuki, and K Hoshi, and A Sato, and H Nakanishi
September 1990, European journal of pharmacology,
T Okawa, and H Suzuki, and C Endo, and Y Suzuki, and K Hoshi, and A Sato, and H Nakanishi
January 1989, European journal of pharmacology,
T Okawa, and H Suzuki, and C Endo, and Y Suzuki, and K Hoshi, and A Sato, and H Nakanishi
April 1992, American journal of obstetrics and gynecology,
T Okawa, and H Suzuki, and C Endo, and Y Suzuki, and K Hoshi, and A Sato, and H Nakanishi
September 1992, The European respiratory journal,
T Okawa, and H Suzuki, and C Endo, and Y Suzuki, and K Hoshi, and A Sato, and H Nakanishi
July 2000, British journal of pharmacology,
Copied contents to your clipboard!